Methods for Treating Ulcerative Colitis
AssigneeFinch Therapeutics Holdings LLC
InventorThomas Julius BORODY
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods and treatment regimens for treating ulcerative colitis in a subject in need thereof. In particular, the methods described herein comprise treating a subject in need thereof with a treatment regimen comprising the administration of a pharmaceutical composition comprising live non-pathogenic fecal bacteria for at least 8 weeks and at least three times per week. In an aspect, the subject in need thereof exhibits a Mayo endoscopy score of 3 or lower. In some aspects, the subject in need thereof has no concomitant corticosteroid use during said method and has no corticosteroid use immediately prior to commencing said method.
Claims20
A method for treating ulcerative colitis (UC) in a subject in need thereof comprising treating said subject with a treatment regimen comprising the administration of a pharmaceutical composition comprising live non-pathogenic fecal bacteria for at least 4 weeks and at least once per week, wherein said treatment regimen is capable of achieving a primary outcome rate of at least two fold higher relative to a primary outcome rate from placebo, wherein said primary outcome is defined as a steroid-free clinical remission and endoscopic remission or response at the end of said treatment regimen, wherein said clinical remission is defined as a total Mayo score of 2 or lower with all sub-scores of 1 or lower, wherein said endoscopic remission or response is defined as a reduction of at least 1 point from baseline in Mayo endoscopy score.
A method for treating ulcerative colitis (UC) in a subject in need thereof and exhibiting a Mayo endoscopy score of 3 or lower, said method comprising administering to said subject a pharmaceutical composition comprising live non-pathogenic fecal bacteria.
A method for treating ulcerative colitis (UC) in a subject in need thereof, said method comprising administering to said subject a pharmaceutical composition comprising live non-pathogenic fecal bacteria, wherein said subject has no concomitant corticosteroid use during said method and has no corticosteroid use immediately prior to commencing said method.
Dependencies are inferred from the claim text.